These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35007149)

  • 1. Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy : A Propensity Score-Matched Cohort Study.
    Hayes KN; Brown KA; Cheung AM; Kim SA; Juurlink DN; Cadarette SM
    Ann Intern Med; 2022 Mar; 175(3):335-343. PubMed ID: 35007149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
    Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Solomon DH
    Ann Intern Med; 2008 May; 148(9):637-46. PubMed ID: 18458276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
    Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
    Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
    Grima DT; Papaioannou A; Thompson MF; Pasquale MK; Adachi JD
    Osteoporos Int; 2008 May; 19(5):687-97. PubMed ID: 18008100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Oral Bisphosphonate Drug Holiday on Mortality Following Hip Fracture.
    Leung MTY; Turner JP; Marquina C; Ilomaki J; Tran T; Bell JS
    J Clin Endocrinol Metab; 2024 Oct; 109(11):2793-2801. PubMed ID: 38630464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk.
    Curtis JR; Saag KG; Arora T; Wright NC; Yun H; Daigle S; Matthews R; Delzell E
    Med Care; 2020 May; 58(5):419-426. PubMed ID: 31985584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
    Silverman SL; Watts NB; Delmas PD; Lange JL; Lindsay R
    Osteoporos Int; 2007 Jan; 18(1):25-34. PubMed ID: 17106785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
    Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
    Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.
    Watts NB; Worley K; Solis A; Doyle J; Sheer R
    J Manag Care Pharm; 2004; 10(2):142-51. PubMed ID: 15032563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
    Pazianas M; Abrahamsen B; Wang Y; Russell RG
    Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
    Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
    Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
    Lin TC; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
    Berto P; Maggi S; Noale M; Lopatriello S
    Aging Clin Exp Res; 2010 Apr; 22(2):179-88. PubMed ID: 20145427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hip fractures in users of first- vs. second-generation bisphosphonates.
    Mamdani M; Kopp A; Hawker G
    Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.
    Goeree R; Burke N; Jobin M; Brown JP; Lawrence D; Stollenwerk B; Willems D; Johnson B
    Arch Osteoporos; 2022 Apr; 17(1):71. PubMed ID: 35471711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses.
    Amiche MA; Lévesque LE; Gomes T; Adachi JD; Cadarette SM
    J Bone Miner Res; 2018 Mar; 33(3):419-429. PubMed ID: 29068496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.